,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,192,1,1,,105753,2230,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
1,248,1,1,,105753,2230,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
2,357,2,1,,11110758,2230,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
3,357,2,1,,11110759,2230,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
4,410,1,5,,11110758,2230,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
5,410,1,5,,11110759,2230,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
6,411,2,1,,11110758,2230,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
7,411,2,1,,11110759,2230,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
8,444,1,1,,11110758,2230,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
9,444,1,1,,11110759,2230,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
10,445,3,1,,11110758,2230,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
11,445,3,1,,11110759,2230,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
12,446,1,1,,11110758,2230,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
13,446,1,1,,11110759,2230,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
14,447,1,1,,11110758,2230,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
15,447,1,1,,11110759,2230,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
16,448,1,2,,11110758,2230,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
17,448,1,2,,11110759,2230,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
18,450,1,2,,11110758,2230,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
19,450,1,2,,11110759,2230,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
20,451,1,2,,11110758,2230,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
21,451,1,2,,11110759,2230,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
22,526,1,1,,11110758,2230,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
23,526,1,1,,11110759,2230,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
24,530,1,1,,11110758,2230,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
25,530,1,1,,11110759,2230,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
26,584,1,3,,11110758,2230,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
27,584,1,3,,11110759,2230,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
28,585,1,4,,11110758,2230,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
29,585,1,4,,11110759,2230,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
30,587,1,5,,11110758,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
31,587,1,5,,11110759,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
32,588,1,4,,11110758,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
33,588,1,4,,11110759,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
34,589,1,3,,11110758,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
35,589,1,3,,11110759,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
36,590,1,3,,11110758,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
37,590,1,3,,11110759,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
38,591,1,4,,11110758,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
39,591,1,4,,11110759,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
40,592,1,6,,11110758,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
41,592,1,6,,11110759,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
42,593,1,4,,11110758,2230,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
43,593,1,4,,11110759,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
44,594,1,4,,11110758,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
45,594,1,4,,11110759,2230,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
46,595,1,3,,11110758,2230,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
47,595,1,3,,11110759,2230,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
48,596,1,2,,11110758,2230,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
49,596,1,2,,11110759,2230,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
50,597,1,3,,11110758,2230,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
51,597,1,3,,11110759,2230,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
52,603,1,2,,11110758,2230,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
53,603,1,2,,11110759,2230,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
54,605,1,2,,11110758,2230,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
55,605,1,2,,11110759,2230,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
56,607,1,3,,11110758,2230,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
57,607,1,3,,11110759,2230,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
58,608,1,6,,11537666,2230,Inactive,17149836.0,2280.0,,,NMR Based Screening Assay for FKBP12,Other,,
59,662,1,1,,11110758,2230,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
60,662,1,1,,11110759,2230,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
61,875,1,2,,11110758,2230,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
62,875,1,2,,11110759,2230,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
63,879,1,2,,11110758,2230,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
64,879,1,2,,11110758,2230,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
65,880,2,1,,11110759,2230,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
66,880,2,1,,11110759,2230,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
67,880,2,1,,26755647,2230,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
68,880,2,1,,26755647,2230,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
69,881,2,2,,11110758,2230,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
70,881,2,2,,11110759,2230,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
71,883,1,3,,11110758,2230,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
72,883,1,3,,11110759,2230,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
73,884,1,2,,11110758,2230,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
74,884,1,2,,11110759,2230,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
75,885,1,2,,11110758,2230,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
76,885,1,2,,11110759,2230,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
77,886,1,2,,11110758,2230,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
78,886,1,2,,11110758,2230,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
79,886,1,2,,11110759,2230,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
80,886,1,2,,11110759,2230,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
81,887,1,2,,11110758,2230,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
82,887,1,2,,11110759,2230,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
83,889,1,3,,11110758,2230,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
84,889,1,3,,11110759,2230,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
85,891,1,2,,11110758,2230,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
86,891,1,2,,11110759,2230,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
87,892,1,2,,11110758,2230,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
88,892,1,2,,11110759,2230,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
89,893,1,2,,11110758,2230,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
90,893,1,2,,11110758,2230,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
91,893,1,2,,11110759,2230,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
92,893,1,2,,11110759,2230,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
93,894,2,1,,11110759,2230,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
94,895,1,2,,11110758,2230,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
95,899,1,2,,11110758,2230,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
96,899,1,2,,11110759,2230,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
97,900,1,3,,11110758,2230,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
98,900,1,3,,11110759,2230,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
99,901,1,2,,11110758,2230,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
100,901,1,2,,11110759,2230,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
101,902,1,2,,11110758,2230,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
102,902,1,2,,11110759,2230,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
103,912,1,2,,11110758,2230,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
104,912,1,2,,11110759,2230,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
105,914,1,3,,11110758,2230,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
106,914,1,3,,11110759,2230,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
107,915,1,3,,11110758,2230,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
108,915,1,3,,11110759,2230,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
109,917,1,3,,11110758,2230,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
110,918,1,3,,11110758,2230,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
111,923,1,2,,11110758,2230,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
112,923,1,2,,11110759,2230,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
113,924,1,2,,11110758,2230,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
114,924,1,2,,11110759,2230,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
115,925,1,2,,11110758,2230,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
116,925,1,2,,11110759,2230,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
117,926,1,2,,11110758,2230,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
118,926,1,2,,11110759,2230,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
119,927,1,3,,11110758,2230,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
120,927,1,3,,11110759,2230,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
121,928,1,2,,11110758,2230,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
122,938,1,2,,11110758,2230,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
123,938,1,2,,11110759,2230,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
124,943,1,2,,11110758,2230,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
125,944,1,2,,11110758,2230,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
126,945,1,4,,11110758,2230,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
127,954,1,2,,11110758,2230,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
128,957,1,2,,11110758,2230,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
129,958,1,2,,11110758,2230,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
130,959,1,4,,11110758,2230,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
131,992,1,3,,11110758,2230,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
132,995,1,2,,11110758,2230,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
133,995,1,2,,11110759,2230,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
134,997,1,2,,11110758,2230,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
135,998,1,2,,11110758,2230,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
136,1030,2,1,,11110759,2230,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
137,1030,2,1,,26755647,2230,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
138,1033,2,2,,11537666,2230,Inactive,216546.0,,,,NMR Based Screening Assay for the substrate binding domain of the chaperone DnaK,Screening,,
139,1195,1,2,,48415577,2230,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
140,1332,1,1,,49698472,2230,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
141,1379,1,2,,11110759,2230,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
142,1452,1,1,,11110758,2230,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
143,1452,1,1,,11110759,2230,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
144,1454,1,1,,11110759,2230,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
145,1457,1,1,,11110759,2230,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
146,1457,1,1,,26755647,2230,Inactive,44888968.0,83523.0,3.5481,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
147,1458,1,1,,11110759,2230,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
148,1458,1,1,,26755647,2230,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
149,1460,1,3,,26755647,2230,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
150,1463,1,1,,26755647,2230,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
151,1467,1,3,,11110759,2230,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
152,1468,1,1,,26755647,2230,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
153,1469,1,1,,11110759,2230,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
154,1469,1,1,,26755647,2230,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
155,1471,2,1,,11110758,2230,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
156,1471,2,1,,11110759,2230,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
157,1471,2,1,,26755647,2230,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
158,1476,2,1,,11110759,2230,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
159,1477,1,1,,11110759,2230,Inconclusive,,,19.9526,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
160,1477,1,1,,26755647,2230,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
161,1478,2,1,,11110759,2230,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
162,1479,1,2,,11110759,2230,Inconclusive,189491771.0,7068.0,0.0355,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
163,1479,1,2,,26755647,2230,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
164,1487,1,1,,11110759,2230,Inconclusive,27436948.0,4000.0,1.0,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
165,1490,2,1,,11110759,2230,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
166,1490,2,1,,26755647,2230,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
167,1519,1,3,,11110759,2230,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
168,1549,1,2,,11537666,2230,Inactive,89033149.0,,,,NMR Based Screening Assay for Novel Chemotypes against influenza A virus,Other,,
169,1552,1,3,,11537666,2230,Inactive,4507793.0,7334.0,,,NMR assay targeting the ubiquitin-proteasome system to modulate protein folding and degradation,Other,,
170,1637,1,2,,11537666,2230,Inactive,,,,,NMR Based Screening Assay for Influenza A RNA Promoter,Other,,
171,1648,1,2,,11537666,2230,Inactive,159164579.0,,,,NMR Based Screening Assay For Novel Chemical Probes Targeting The FRB Domain of mTOR,Other,,
172,1688,1,1,,26755647,2230,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
173,1766,1,1,,11110759,2230,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
174,1766,1,1,,11110759,2230,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
175,1766,1,1,,26755647,2230,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
176,1766,1,1,,26755647,2230,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
177,1768,1,1,,11110759,2230,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
178,1768,1,1,,11110759,2230,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
179,1768,1,1,,26755647,2230,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
180,1768,1,1,,26755647,2230,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
181,1851,1,2,,11110758,2230,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
182,1851,1,2,,11110759,2230,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
183,1851,1,2,1.0,11110758,2230,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
184,1851,1,2,1.0,11110759,2230,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
185,1851,1,2,2.0,11110758,2230,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
186,1851,1,2,2.0,11110759,2230,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
187,1851,1,2,3.0,11110758,2230,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
188,1851,1,2,3.0,11110759,2230,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
189,1851,1,2,4.0,11110758,2230,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
190,1851,1,2,4.0,11110759,2230,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
191,1851,1,2,5.0,11110758,2230,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
192,1851,1,2,5.0,11110759,2230,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
193,1865,1,1,,11110759,2230,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
194,1865,1,1,,26755647,2230,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
195,1948,1,1,,11110759,2230,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
196,2062,1,2,,85209508,2230,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
197,2101,1,1,,11110759,2230,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
198,2101,1,1,,26755647,2230,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
199,2107,1,1,,11110759,2230,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
200,2107,1,1,,26755647,2230,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
201,2112,1,1,,11110759,2230,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
202,2112,1,1,,26755647,2230,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
203,2147,1,1,,11110759,2230,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
204,2240,1,1,,85788884,2230,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
205,2241,1,1,,85788884,2230,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
206,2275,1,1,,85788884,2230,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
207,2313,1,1,,85788884,2230,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
208,2322,1,1,,85788884,2230,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
209,2330,1,1,,85788884,2230,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
210,2451,1,2,,11110759,2230,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
211,2472,1,2,,11110759,2230,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
212,2517,2,1,,11110759,2230,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
213,2517,2,1,,26755647,2230,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
214,2528,1,2,,11110759,2230,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
215,2528,1,2,,26755647,2230,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
216,2546,1,1,,11110759,2230,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
217,2546,1,1,,26755647,2230,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
218,2549,1,1,,11110759,2230,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
219,2549,1,1,,26755647,2230,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
220,2551,1,1,,11110759,2230,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
221,2551,1,1,,26755647,2230,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
222,2660,1,1,,90341790,2230,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
223,2666,1,1,,90341790,2230,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
224,2667,1,1,,90341790,2230,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
225,2668,1,1,,90341790,2230,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
226,9449,6,2,,103164643,2230,Active,,,1.2,IC50,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Confirmatory,9111297.0,
227,9450,3,4,,103164643,2230,Unspecified,,,,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Other,9111297.0,
228,9454,6,2,,103164643,2230,Unspecified,,,3080.0,EC50,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",Confirmatory,7658434.0,
229,9455,4,4,,103164643,2230,Unspecified,,,,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,Other,7658434.0,
230,26318,3,3,,103164643,2230,Unspecified,,,,,Dissociation constant (pKa),Other,3712371.0,
231,73733,6,2,,103164643,2230,Active,,,0.15,EC50,Effective concentration of compound for the agonistic activity on guinea pig ileum,Confirmatory,3385727.0,
232,75929,6,3,,103164643,2230,Active,,,0.073,EC50,Agonist activity at muscarinic acetylcholine receptor in isolated guinea pig ileum.,Confirmatory,1995893.0,
233,78071,3,6,,103164643,2230,Unspecified,,,,,Maximal contraction compared to acetylcholine in isolated guinea pig ileum,Other,1995893.0,
234,78151,6,2,,103164643,2230,Unspecified,,,1.0,IC50,Compound was tested for the antagonistic activity on guinea pig ileum,Confirmatory,3385727.0,
235,78185,3,3,,103164643,2230,Unspecified,,,,,In vitro inhibition of maximum force of contraction in guinea pig atria.,Other,1613751.0,
236,78308,4,3,,103164643,2230,Active,,,0.6,IC50,In vitro inhibition of force of contraction in guinea pig atria.,Confirmatory,1613751.0,
237,79365,2,5,,103164643,2230,Unspecified,,,,,Evaluated for the percent efficacy in guinea pig ileum contraction model,Other,,
238,79383,2,5,,103164643,2230,Unspecified,,,,,Evaluated for the muscarinic potency in guinea pig ileum contraction model,Other,,
239,101732,3,10,,103164643,2230,Unspecified,81915994.0,,,,Peripheral postsynaptic muscarinic activity was measured relative to muscarine (100%),Other,1732522.0,
240,101734,3,10,,103164643,2230,Unspecified,81915994.0,,,,Peripheral postsynaptic muscarinic activity by contraction of the guinea pig ileum.,Other,1732522.0,
241,104017,9,5,,103164643,2230,Active,113121.0,25229.0,1.0,IC50,Inhibition of [3H]-(R)-QNB binding to muscarinic receptors of rat brain membranes.,Confirmatory,8464038.0,
242,104017,9,5,,103164643,2230,Active,113127.0,24260.0,1.0,IC50,Inhibition of [3H]-(R)-QNB binding to muscarinic receptors of rat brain membranes.,Confirmatory,8464038.0,
243,104017,9,5,,103164643,2230,Active,113130.0,25111.0,1.0,IC50,Inhibition of [3H]-(R)-QNB binding to muscarinic receptors of rat brain membranes.,Confirmatory,8464038.0,
244,104017,9,5,,103164643,2230,Active,113132.0,53949.0,1.0,IC50,Inhibition of [3H]-(R)-QNB binding to muscarinic receptors of rat brain membranes.,Confirmatory,8464038.0,
245,104017,9,5,,103164643,2230,Active,12643977.0,81645.0,1.0,IC50,Inhibition of [3H]-(R)-QNB binding to muscarinic receptors of rat brain membranes.,Confirmatory,8464038.0,
246,112960,6,2,,103164643,2230,Unspecified,,,,,Compound was tested for its ability to induce salivation in mice upon subcutaneous administration,Other,9438027.0,
247,112961,6,2,,103164643,2230,Unspecified,,,,,Compound was tested for its ability to induce tremors in mice subcutaneous administration,Other,9438027.0,
248,113180,6,2,,103164643,2230,Unspecified,,,,,In vivo antinociceptive activity was measured using mouse grid shock (MGS) assay in mice upon subcutaneous administration,Other,9438027.0,
249,119583,4,4,,103164643,2230,Unspecified,,,,,"Effect on salivation in mice, after intraperitoneal administration of 10 mg/kg, activity expressed as a score using a scale of 0-2.",Other,7658434.0,
250,140947,9,1,,103164643,2230,Active,,,4.5,IC50,Compound was evaluated for its ability to displace [3H]- N-methyl-scopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M2,Confirmatory,9438027.0,
251,140972,7,2,,103164643,2230,Active,,,0.04,Ki,Binding affinity for muscarinic receptor site in rat hippocampus was determined using competitive radioligand binding assays employing [3H]OXO-M,Confirmatory,,
252,140993,4,5,,103164643,2230,Active,,,0.14,EC50,M2/M3 agonist activity estimated by contraction of isolated guinea pig ileum,Confirmatory,7990109.0,
253,141037,9,2,,103164643,2230,Active,,,3.2,EC50,In Vitro evaluation activity at the cloned Human Muscarinic acetylcholine receptor M1 determined by receptor selection and amplification technology (R-SAT),Confirmatory,7783150.0,
254,141040,9,5,,103164643,2230,Unspecified,113118.0,1128.0,115.5,IC50,Ability to displace [3H]N-methylscopolamine from Muscarinic acetylcholine receptor M1 expressed in CHO cells.,Confirmatory,11597415.0,
255,141041,9,5,,103164643,2230,Active,113118.0,1128.0,0.115,IC50,Ability to displace [3H]oxotremorine from Muscarinic acetylcholine receptor M1 expressed in CHO cells.,Confirmatory,11597415.0,
256,141052,8,5,,103164643,2230,Unspecified,113118.0,1128.0,65.0,IC50,In vitro affinity against human Muscarinic acetylcholine receptor M1 using quinuclidynyl benzylate (QNB),Confirmatory,9435896.0,
257,141057,3,6,,103164643,2230,Unspecified,,,,,Inhibition of binding of [3H]- quinuclidinyl benzilate to Muscarinic acetylcholine receptor M1 in membranes of CHO cells at 100 uM compound concentration,Other,10891110.0,
258,141058,3,7,,103164643,2230,Unspecified,,,,,"Percentage affinity versus [3H]quinuclidinyl benzilate (antagonist) binding to Muscarinic acetylcholine receptor M1 in Rat Cerebral Cortical Membranes, (Kd=0.26 nM)",Other,9622546.0,
259,141130,9,1,,103164643,2230,Active,,,0.1,EC50,"Contraction of guinea pig ileum by muscarinic AChR activation, which could be inhibited by application of atropine",Confirmatory,3712371.0,
260,141169,9,2,,103164643,2230,Active,,,29.0,Ki,Binding affinity of compound was determined towards human Muscarinic acetylcholine receptor M1 using [3H]QNB radioligand,Confirmatory,12747793.0,
261,141179,9,5,,103164643,2230,Active,113118.0,1128.0,0.013999999999999999,Ki,Inhibition of [3H]- oxotremorine-M binding to human Muscarinic acetylcholine receptor M1 expressed in CHO cell membranes,Confirmatory,10891110.0,
262,141319,9,5,,103164643,2230,Active,408359949.0,12669.0,27.0,EC50,Tested against Muscarinic acetylcholine receptor M1 expressed in A9 L cell line,Confirmatory,9111297.0,
263,141345,9,2,,103164643,2230,Active,,,0.34,EC50,In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M3 determined by receptor selection and amplification technology (R-SAT),Confirmatory,7783150.0,
264,141349,7,2,,103164643,2230,Active,,,11.0,IC50,"In vitro affinity is evaluated, using quinuclidynyl benzylate (QNB) as radioligand in human cloned Muscarinic acetylcholine receptor M3",Confirmatory,9435896.0,
265,141430,3,10,,103164643,2230,Unspecified,408359949.0,12669.0,,,Percent inhibition (low) of [3H]-(R)-QNB binding to Muscarinic acetylcholine receptor M1 expressed in A9 L cell line in the absence of 300 uM GTP-gamma-S,Other,9111297.0,
266,141431,3,10,,103164643,2230,Unspecified,408359949.0,12669.0,,,Percent inhibition of [3H]-(R)-QNB binding to Muscarinic acetylcholine receptor M1 expressed in A9 L cell line in the presence of 300 uM GTP-gamma-S,Other,9111297.0,
267,141434,8,5,,103164643,2230,Active,408359949.0,12669.0,0.0033299999999999996,Ki,Binding affinity (low) of [3H](R)-QNB binding to Muscarinic acetylcholine receptor M1 expressed in A9 L cell line in the absence of 300 uM GTP-gamma-S,Confirmatory,9111297.0,
268,141435,8,5,,103164643,2230,Active,408359949.0,12669.0,0.00545,Ki,Binding affinity of [3H]-(R)-QNB binding to Muscarinic acetylcholine receptor M1 expressed in A9 L cell line in the presence of 300 uM GTP-gamma-S,Confirmatory,9111297.0,
269,141436,3,6,,103164643,2230,Unspecified,,,,,Maximum stimulation at Muscarinic acetylcholine receptor M1 expressed in A9 L cells,Other,9111297.0,
270,141467,9,2,,103164643,2230,Active,,,43.0,Ki,Binding affinity of compound was determined towards human Muscarinic acetylcholine receptor M3 using [3H]QNB radioligand,Confirmatory,12747793.0,
271,141470,9,1,,103164643,2230,Active,,,5.7,Ki,Inhibition of binding of [3H]quinuclidinyl benzilate to muscarinic receptors in membranes of CHO cells transfected with Muscarinic acetylcholine receptor M3,Confirmatory,9622546.0,
272,141472,8,8,,103164643,2230,Inconclusive,113125.0,1131.0,,,Inhibition of [3H]- oxotremorine-M binding to human Muscarinic acetylcholine receptor M3 expressed in CHO cell membranes,Other,10891110.0,
273,141529,7,1,,103164643,2230,Active,,,0.115,IC50,In vitro ability to displace [3H]oxotremorine-M (OXO-M) from rat cerebral cortex Muscarinic acetylcholine receptor,Confirmatory,1619616.0,
274,141532,7,1,,103164643,2230,Active,,,25.4,IC50,In vitro ability to displace [3H]quinuclidinyl benzilate (QNB) from rat cerebral cortex Muscarinic acetylcholine receptor,Confirmatory,1619616.0,
275,141540,7,1,,103164643,2230,Active,,,0.02,IC50,"Ability to displace [3H]cis--2-methyl-5-((dimethylamino)methyl)-1,3-di oxolane from muscarinic acetylcholine receptor in rat cortical tissue.",Confirmatory,1732522.0,
276,141541,9,5,,103164643,2230,Active,113121.0,25229.0,0.0019,IC50,Inhibition of [3H]oxotremorine-M binding to rat brain membrane Muscarinic acetylcholine receptor,Confirmatory,3385727.0,
277,141541,9,5,,103164643,2230,Active,113127.0,24260.0,0.0019,IC50,Inhibition of [3H]oxotremorine-M binding to rat brain membrane Muscarinic acetylcholine receptor,Confirmatory,3385727.0,
278,141541,9,5,,103164643,2230,Active,113130.0,25111.0,0.0019,IC50,Inhibition of [3H]oxotremorine-M binding to rat brain membrane Muscarinic acetylcholine receptor,Confirmatory,3385727.0,
279,141541,9,5,,103164643,2230,Active,113132.0,53949.0,0.0019,IC50,Inhibition of [3H]oxotremorine-M binding to rat brain membrane Muscarinic acetylcholine receptor,Confirmatory,3385727.0,
280,141541,9,5,,103164643,2230,Active,12643977.0,81645.0,0.0019,IC50,Inhibition of [3H]oxotremorine-M binding to rat brain membrane Muscarinic acetylcholine receptor,Confirmatory,3385727.0,
281,141542,9,2,,103164643,2230,Active,,,5.6,IC50,Inhibition of binding of radioactive N-propylbenzilycholine mustard ([3H]-PrBCM) to rat brain membranes,Confirmatory,3712371.0,
282,141543,7,5,,103164643,2230,Active,113121.0,25229.0,0.115,IC50,In vitro inhibition of [3H]OXO-M binding to Muscarinic receptor from rat cortical homogenates,Confirmatory,1560440.0,
283,141543,7,5,,103164643,2230,Active,113127.0,24260.0,0.115,IC50,In vitro inhibition of [3H]OXO-M binding to Muscarinic receptor from rat cortical homogenates,Confirmatory,1560440.0,
284,141543,7,5,,103164643,2230,Active,113130.0,25111.0,0.115,IC50,In vitro inhibition of [3H]OXO-M binding to Muscarinic receptor from rat cortical homogenates,Confirmatory,1560440.0,
285,141543,7,5,,103164643,2230,Active,113132.0,53949.0,0.115,IC50,In vitro inhibition of [3H]OXO-M binding to Muscarinic receptor from rat cortical homogenates,Confirmatory,1560440.0,
286,141543,7,5,,103164643,2230,Active,12643977.0,81645.0,0.115,IC50,In vitro inhibition of [3H]OXO-M binding to Muscarinic receptor from rat cortical homogenates,Confirmatory,1560440.0,
287,141544,8,5,,103164643,2230,Active,113121.0,25229.0,25.4,IC50,In vitro inhibition of [3H]QNB binding to Muscarinic receptor from rat cortical homogenates,Confirmatory,1560440.0,
288,141544,8,5,,103164643,2230,Active,113127.0,24260.0,25.4,IC50,In vitro inhibition of [3H]QNB binding to Muscarinic receptor from rat cortical homogenates,Confirmatory,1560440.0,
289,141544,8,5,,103164643,2230,Active,113130.0,25111.0,25.4,IC50,In vitro inhibition of [3H]QNB binding to Muscarinic receptor from rat cortical homogenates,Confirmatory,1560440.0,
290,141544,8,5,,103164643,2230,Active,113132.0,53949.0,25.4,IC50,In vitro inhibition of [3H]QNB binding to Muscarinic receptor from rat cortical homogenates,Confirmatory,1560440.0,
291,141544,8,5,,103164643,2230,Active,12643977.0,81645.0,25.4,IC50,In vitro inhibition of [3H]QNB binding to Muscarinic receptor from rat cortical homogenates,Confirmatory,1560440.0,
292,141550,7,1,,103164643,2230,Active,,,0.077,IC50,In vitro binding affinity to muscarinic acetylcholine receptor site in rat brain assayed using [3H]oxotremorine-M as the radioligand.,Confirmatory,1995893.0,
293,141551,9,1,,103164643,2230,Unspecified,,,106.0,IC50,In Vitro binding affinity to the muscarinic acetylcholine receptor site in rat brain by using [3H]QNB as the radioligand.,Confirmatory,1995893.0,
294,141552,7,1,,103164643,2230,Active,,,0.0627,IC50,In vitro Binding affinity was measured against Muscarinic acetylcholine receptor on rat brain membranes using [3H]oxotremorine-M,Confirmatory,9438027.0,
295,141554,7,1,,103164643,2230,Active,,,1.74,IC50,Ability to displace [3H]pirenzepine (pir) from muscarinic acetylcholine receptor M1 in rat cortical tissue.,Confirmatory,1732522.0,
296,141555,10,5,,103164643,2230,Active,113121.0,25229.0,1.1,IC50,Inhibition of [3H]pirenzepine binding to rat brain membrane Muscarinic acetylcholine receptor M1,Confirmatory,3385727.0,
297,141559,7,1,,103164643,2230,Active,,,0.077,IC50,"In vitro binding affinity against muscarinic acetylcholine receptor M1 from rat hippocampus, using [3H]oxotremorine-M (Oxo-M) as radioligand",Confirmatory,1613751.0,
298,141560,7,1,,103164643,2230,Active,,,1.3,IC50,"In vitro binding affinity against muscarinic acetylcholine receptor M1 from rat hippocampus, using [3H]pirenzepine (Pz) as radioligand",Confirmatory,1613751.0,
299,141565,8,5,,103164643,2230,Active,113121.0,25229.0,0.077,IC50,Displacement of [3H]oxotremorine-M (Oxo-M) from rat hippocampus muscarinic acetylcholine receptor M1,Confirmatory,1433209.0,
300,141566,8,5,,103164643,2230,Active,113121.0,25229.0,1.3,IC50,Displacement of [3H]pirenzepine (Pz) from rat hippocampus muscarinic acetylcholine receptor M1,Confirmatory,1433209.0,
301,141574,7,1,,103164643,2230,Active,,,0.077,IC50,"Binding activity against muscarinic acetylcholine receptor M1 in rat brain, using [3H]OXO-M as the radioligand.",Confirmatory,7658434.0,
302,141575,7,1,,103164643,2230,Active,,,1.3,IC50,"Binding activity against muscarinic acetylcholine receptor M1 in rat brain, using [3H]-Pz as the radioligand.",Confirmatory,7658434.0,
303,141576,4,7,,103164643,2230,Unspecified,,,,,Inhibition of binding of [3H]quinuclidinyl benzilate to Muscarinic acetylcholine receptor M1 in rat cerebral cortical membranes at 100 uM concentration,Other,9622546.0,
304,141581,4,9,,103164643,2230,Unspecified,113121.0,25229.0,,,Percentage inhibition of binding of [3H]quinuclidinyl benzilate to Muscarinic acetylcholine receptor M1 in Rat Cerebral Cortical Membranes,Other,9622546.0,
305,141585,7,1,,103164643,2230,Unspecified,,,,,The binding affinity was measured as inhibition of binding of [3H]- quinuclidinyl benzilate to m3 Muscarinic acetylcholine receptor M3 in membranes of CHO cells,Other,10891110.0,
306,141597,7,6,,103164643,2230,Active,14194438.0,12671.0,12.0,EC50,Tested against Muscarinic acetylcholine receptor M3 expressed in A9 L cell line,Confirmatory,9111297.0,
307,141599,3,10,,103164643,2230,Unspecified,14194438.0,12671.0,,,Percent inhibition (low) of [3H](R)-QNB binding to Muscarinic acetylcholine receptor M3 expressed in A9 L cell line,Other,9111297.0,
308,141601,3,10,,103164643,2230,Active,14194438.0,12671.0,,,Binding affinity (low) of [3H](R)-QNB binding to Muscarinic acetylcholine receptor M3 expressed in A9 L cell line,Other,9111297.0,
309,141602,3,6,,103164643,2230,Unspecified,,,,,Maximum stimulation at Muscarinic acetylcholine receptor M3 expressed in A9 L cells,Other,9111297.0,
310,141659,7,1,,103164643,2230,Active,,,0.115,IC50,In vitro affinity evaluated using [3H]- oxotremorine as radioligand in rat cerebral cortex for muscarinic acetylcholine receptor,Confirmatory,9435896.0,
311,141660,7,1,,103164643,2230,Active,,,19.0,IC50,In vitro affinity evaluated using [3H]- quinuclidinyl benzilate as radioligand in rat cerebral cortex for muscarinic acetylcholine receptor,Confirmatory,9435896.0,
312,141661,9,1,,103164643,2230,Active,,,0.016,IC50,In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]- Oxo-M from the rat brain tissues,Confirmatory,7783150.0,
313,141663,9,1,,103164643,2230,Active,,,2.1,IC50,In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]PZ from the rat brain tissues,Confirmatory,7783150.0,
314,141664,9,1,,103164643,2230,Active,,,28.0,IC50,In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]QNB from the rat brain tissues,Confirmatory,7783150.0,
315,141665,9,2,,103164643,2230,Active,,,1.7,IC50,In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]-QNB from the rat heart tissues,Confirmatory,7783150.0,
316,141729,9,5,,103164643,2230,Active,113127.0,24260.0,5.7,Ki,Inhibition of binding of [3H]quinuclidinyl benzilate to Muscarinic acetylcholine receptor M3 in rat cerebral cortical membranes,Confirmatory,9622546.0,
317,141745,9,1,,103164643,2230,Unspecified,,,58.0,IC50,Compound was evaluated for its ability to displace [3H]N-methylscopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M3,Confirmatory,9438027.0,
318,141848,3,6,,103164643,2230,Unspecified,,,,,Ratio of ability to displace pirenzpine compared to ability to displace CD (non-selective muscarinic agonist).,Other,1732522.0,
319,141856,6,3,,103164643,2230,Active,,,1.7378,IC50,Evaluated for inhibition of binding of [3H]pirenzepine to homogenized rat cerebral cortex membranes,Confirmatory,,
320,141868,9,2,,103164643,2230,Active,,,0.13,EC50,In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M4 determined by receptor selection and amplification technology (R-SAT),Confirmatory,7783150.0,
321,141875,7,2,,103164643,2230,Active,,,13.5,IC50,"In vitro affinity is evaluated, using quinuclidynyl benzylate (QNB) as radioligand in human cloned Muscarinic acetylcholine receptor M4",Confirmatory,9435896.0,
322,141884,9,2,,103164643,2230,Unspecified,,,60.0,Ki,Binding affinity of compound was determined towards human Muscarinic acetylcholine receptor M4 using [3H]QNB radioligand,Confirmatory,12747793.0,
323,141885,9,5,,103164643,2230,Active,23503039.0,1132.0,2.4,Ki,Inhibition of binding of [3H]quinuclidinyl benzilate to muscarinic receptors in membranes of CHO cells transfected with Muscarinic acetylcholine receptor M4,Confirmatory,9622546.0,
324,141886,9,5,,103164643,2230,Active,23503039.0,1132.0,0.026000000000000002,Ki,Inhibition of [3H]- oxotremorine-M binding to human Muscarinic acetylcholine receptor M4 in CHO cell membranes,Confirmatory,10891110.0,
325,141887,9,5,,103164643,2230,Active,23503039.0,1132.0,2.4,Ki,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor M4 expressed in CHO cell membranes,Confirmatory,10891110.0,
326,141946,3,10,,103164643,2230,Unspecified,113121.0,25229.0,,,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat cerebral cortical membranes at 100 uM,Other,10891110.0,
327,141946,3,10,,103164643,2230,Unspecified,113127.0,24260.0,,,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat cerebral cortical membranes at 100 uM,Other,10891110.0,
328,141946,3,10,,103164643,2230,Unspecified,113130.0,25111.0,,,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat cerebral cortical membranes at 100 uM,Other,10891110.0,
329,141946,3,10,,103164643,2230,Unspecified,113132.0,53949.0,,,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat cerebral cortical membranes at 100 uM,Other,10891110.0,
330,141946,3,10,,103164643,2230,Unspecified,12643977.0,81645.0,,,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat cerebral cortical membranes at 100 uM,Other,10891110.0,
331,141973,9,1,,103164643,2230,Unspecified,,,145.0,IC50,Compound was evaluated for its ability to displace [3H]N-methylscopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M1,Confirmatory,9438027.0,
332,142014,9,5,,103164643,2230,Active,113130.0,25111.0,2.4,Ki,Inhibition of binding of [3H]quinuclidinyl benzilate to Muscarinic acetylcholine receptor M4 in rat cerebral cortical membranes,Confirmatory,9622546.0,
333,142022,9,1,,103164643,2230,Active,,,47.5,IC50,Compound was evaluated for its ability to displace [3H]- N-methyl-scopolamine ([3H]-NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M4,Confirmatory,9438027.0,
334,142085,7,1,,103164643,2230,Active,,,,,Ability to displace radioligand [3H]N-methylscopolamine (NMS) at muscarinic acetylcholine receptor from rat cortical homogenate.,Other,2362286.0,
335,142087,7,1,,103164643,2230,Active,,,,,Affinity to displace radioligand [3H]oxotremorine (OXO) at muscarinic acetylcholine receptor from rat cortical homogenate.,Other,2362286.0,
336,142088,7,1,,103164643,2230,Active,,,,,Apparent binding affinity at Muscarinic acetylcholine receptor by displacing [3H]oxotremorine-M in rat cortex,Other,3339620.0,
337,142092,7,1,,103164643,2230,Active,,,,,"Apparent binding affinity at v, by displacing [3H]N-methylscopolamine (NMS) in rat cortex",Other,3339620.0,
338,142095,7,1,,103164643,2230,Active,,,,,Apparent binding affinity to rat cortical muscarinic acetylcholine receptor by the displacement of [3H]N-methylscopolamine,Other,2002451.0,
339,142096,7,1,,103164643,2230,Active,,,,,Apparent binding affinity at rat cortical muscarinic acetylcholine receptor by the displacement of [3H]oxotremorine-M.,Other,2002451.0,
340,142097,7,1,,103164643,2230,Active,,,,,In vitro for its ability to displace [3H]NMS from muscarinic acetylcholine receptor in rat cortical homogenates,Other,2319559.0,
341,142098,7,1,,103164643,2230,Active,,,,,In vitro displacement of [3H]OXO-M from muscarinic acetylcholine receptor in rat cortical homogenates,Other,2319559.0,
342,142145,9,2,,103164643,2230,Active,,,0.6,EC50,In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M5 determined by receptor selection and amplification technology (R-SAT),Confirmatory,7783150.0,
343,142154,9,2,,103164643,2230,Unspecified,,,56.0,Ki,Binding affinity of compound was determined towards human Muscarinic acetylcholine receptor M5 using [3H]QNB radioligand,Confirmatory,12747793.0,
344,142209,7,1,,103164643,2230,Active,,,,,In vitro binding affinity against muscarinic acetylcholine receptor from rat cortical homogenates using [3H]N-methylscopolamine as radioligand,Other,2213823.0,
345,142210,7,1,,103164643,2230,Active,,,,,In vitro binding affinity against muscarinic acetylcholine receptor from rat cortical homogenates using [3H]oxotremorine-M radioligand,Other,2213823.0,
346,142211,7,1,,103164643,2230,Active,,,,,In vitro binding affinity against cortical muscarinic acetylcholine receptor measured by displacement of [3H]NMS.,Other,1732546.0,
347,142212,7,1,,103164643,2230,Active,,,,,In vitro binding affinity against cortical muscarinic acetylcholine receptor measured by displacement of [3H]OXO-M.,Other,1732546.0,
348,142281,9,1,,103164643,2230,Unspecified,,,62.5,IC50,Compound was evaluated for its ability to displace [3H]- N-methyl-scopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M5,Confirmatory,9438027.0,
349,142284,4,6,,103164643,2230,Active,,,5.603,EC50,Stimulation of phosphoinositide hydrolysis in A9L cells expressing human m1 receptor,Confirmatory,9873644.0,
350,142299,4,9,,103164643,2230,Unspecified,113118.0,1128.0,,,Stimulation of phosphoinositide hydrolysis in BHK cells expressing human m1 receptor,Other,9873644.0,
351,142300,3,6,,103164643,2230,Unspecified,,,,,Stimulation of phosphoinositide hydrolysis in A9L cells expressing human m1 receptor,Other,9873644.0,
352,142343,9,2,,103164643,2230,Active,,,0.031,Ki,The binding affinity was measured as inhibition of binding of [3H]- oxotremorine-M to muscarinic acetylcholine receptor in rat cerebral cortical membranes.,Confirmatory,10891110.0,
353,142346,9,5,,103164643,2230,Active,113121.0,25229.0,0.0053,Ki,Inhibition of [3H]- oxotremorine-M binding to Muscarinic acetylcholine receptor of rat heart membranes.,Confirmatory,10891110.0,
354,142346,9,5,,103164643,2230,Active,113127.0,24260.0,0.0053,Ki,Inhibition of [3H]- oxotremorine-M binding to Muscarinic acetylcholine receptor of rat heart membranes.,Confirmatory,10891110.0,
355,142346,9,5,,103164643,2230,Active,113130.0,25111.0,0.0053,Ki,Inhibition of [3H]- oxotremorine-M binding to Muscarinic acetylcholine receptor of rat heart membranes.,Confirmatory,10891110.0,
356,142346,9,5,,103164643,2230,Active,113132.0,53949.0,0.0053,Ki,Inhibition of [3H]- oxotremorine-M binding to Muscarinic acetylcholine receptor of rat heart membranes.,Confirmatory,10891110.0,
357,142346,9,5,,103164643,2230,Active,12643977.0,81645.0,0.0053,Ki,Inhibition of [3H]- oxotremorine-M binding to Muscarinic acetylcholine receptor of rat heart membranes.,Confirmatory,10891110.0,
358,142347,9,5,,103164643,2230,Active,113121.0,25229.0,1.9,Ki,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat heart membranes.,Confirmatory,10891110.0,
359,142347,9,5,,103164643,2230,Active,113127.0,24260.0,1.9,Ki,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat heart membranes.,Confirmatory,10891110.0,
360,142347,9,5,,103164643,2230,Active,113130.0,25111.0,1.9,Ki,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat heart membranes.,Confirmatory,10891110.0,
361,142347,9,5,,103164643,2230,Active,113132.0,53949.0,1.9,Ki,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat heart membranes.,Confirmatory,10891110.0,
362,142347,9,5,,103164643,2230,Active,12643977.0,81645.0,1.9,Ki,Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat heart membranes.,Confirmatory,10891110.0,
363,142348,9,1,,103164643,2230,Active,,,7.12,Ki,"Binding affinity against muscarinic acetylcholine receptor from rat brain crude membrane, using [3H]-NMS (N-Methylscopolamine) as the radioligand.",Confirmatory,7739014.0,
364,142349,8,2,,103164643,2230,Active,,,0.0074,Ki,"Binding affinity against muscarinic acetylcholine receptor from rat brain crude membrane, using [3H]OXO-M (oxotremorine) as the radioligand.",Confirmatory,7739014.0,
365,142367,3,7,,103164643,2230,Unspecified,,,,,Ratio of apparent binding affinities of NMS and Oxo-M,Other,2002451.0,
366,142368,4,7,,103164643,2230,Unspecified,,,,,Ratio of geometric mean of the affinity constant (Kapp) of NMS/OXO-M,Other,1732546.0,
367,142369,4,7,,103164643,2230,Unspecified,,,,,The selectivity ratio of Kapp of NMS/OXO -M,Other,2213823.0,
368,142379,9,2,,103164643,2230,Active,,,0.025,EC50,In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M2 determined by receptor selection and amplification technology (R-SAT).,Confirmatory,7783150.0,
369,142394,7,2,,103164643,2230,Active,,,1.8,IC50,"In vitro affinity is evaluated, using quinuclidynyl benzylate (QNB) as radioligand in human cloned Muscarinic acetylcholine receptor M2",Confirmatory,9435896.0,
370,142417,4,7,,103164643,2230,Active,,,10.0,EC50,Stimulation of cAMP in CHO cells expressing human m2 receptor,Confirmatory,9873644.0,
371,142430,4,7,,103164643,2230,Unspecified,,,,,Stimulation of cAMP in CHO cells expressing human m2 receptor,Other,9873644.0,
372,142488,8,3,,103164643,2230,Active,,,1.0,IC50,Inhibition of specific [3H](R)-QNB binding to Muscarinic acetylcholine receptor in rat brain membranes,Confirmatory,9111297.0,
373,142519,9,2,,103164643,2230,Active,,,2.4,Ki,Binding affinity of compound was determined towards human Muscarinic acetylcholine receptor M2 using [3H]QNB radioligand,Confirmatory,12747793.0,
374,142529,9,5,,103164643,2230,Active,113122.0,1129.0,0.04,Ki,Inhibition of binding of [3H]quinuclidinyl benzilate to muscarinic receptors in membranes of CHO cells transfected with Muscarinic acetylcholine receptor M2,Confirmatory,9622546.0,
375,142531,9,1,,103164643,2230,Active,,,0.04,Ki,The binding affinity was measured as inhibition of binding of [3H]- oxotremorine-M m2 toMuscarinic acetylcholine receptor M2 in membranes of CHO cells,Confirmatory,10891110.0,
376,142532,9,5,,103164643,2230,Active,113122.0,1129.0,0.04,Ki,Inhibition of [3H]- quinuclidinyl benzilate binding to human Muscarinic acetylcholine receptor M2 expressed in CHO cell membrane,Confirmatory,10891110.0,
377,142613,4,9,,103164643,2230,Unspecified,113121.0,25229.0,0.22,EC50,M1 agonist activity estimated by rat superior cervical ganglion depolarization,Confirmatory,7990109.0,
378,142663,3,10,,103164643,2230,Unspecified,341940175.0,243764.0,,,Percent inhibition (low) of [3H](R)-QNB binding to Muscarinic acetylcholine receptor M2 expressed in A9 L cell line,Other,9111297.0,
379,142664,3,10,,103164643,2230,Unspecified,341940175.0,243764.0,,,Percent inhibition (medium) of [3H]-(R)-QNB binding to Muscarinic acetylcholine receptor M2 expressed in A9 L cell line,Other,9111297.0,
380,142666,3,10,,103164643,2230,Active,341940175.0,243764.0,,,Binding affinity (low) of [3H]-(R)-QNB binding to Muscarinic acetylcholine receptor M2 expressed in A9 L cell line,Other,9111297.0,
381,142667,5,8,,103164643,2230,Active,341940175.0,243764.0,0.0024,Km,Binding affinity (medium) of [3H](R)-QNB binding to Muscarinic acetylcholine receptor M2 expressed in A9 L cell line,Confirmatory,9111297.0,
382,142693,9,1,,103164643,2230,Active,,,1.0,IC50,Affinity for muscarinic receptor in rat brain was measured by inhibition of [3H](R)-quinuclidinyl benzilate (QNB) binding,Confirmatory,8064804.0,
383,142711,9,5,,103164643,2230,Active,113121.0,25229.0,1.0,IC50,Inhibition of [3H](R)-QNB binding to muscarinic receptor in rat brain membranes,Confirmatory,,
384,142711,9,5,,103164643,2230,Active,113127.0,24260.0,1.0,IC50,Inhibition of [3H](R)-QNB binding to muscarinic receptor in rat brain membranes,Confirmatory,,
385,142711,9,5,,103164643,2230,Active,113130.0,25111.0,1.0,IC50,Inhibition of [3H](R)-QNB binding to muscarinic receptor in rat brain membranes,Confirmatory,,
386,142711,9,5,,103164643,2230,Active,113132.0,53949.0,1.0,IC50,Inhibition of [3H](R)-QNB binding to muscarinic receptor in rat brain membranes,Confirmatory,,
387,142711,9,5,,103164643,2230,Active,12643977.0,81645.0,1.0,IC50,Inhibition of [3H](R)-QNB binding to muscarinic receptor in rat brain membranes,Confirmatory,,
388,142712,7,2,,103164643,2230,Active,,,11.92,IC50,Compound was evaluated for the displacement of the muscarinic QNB in a genetically transformed rat cell line (m1c2) transfected with cloned m1 receptors (m1-QNBm1c2),Confirmatory,,
389,142713,8,5,,103164643,2230,Active,113121.0,25229.0,1.3,IC50,Displacement of [3H]-Pz (pirenzepine) from the muscarinic receptor M1 of the rat hippocampus,Confirmatory,,
390,142742,7,1,,103164643,2230,Active,,,0.083,EC50,In vitro binding affinity for muscarinic M1 receptor by displacing [3H]Pirenzepine binding on rat brain homogenate,Confirmatory,7990109.0,
391,142805,9,5,,103164643,2230,Active,12643977.0,81645.0,11.0,IC50,Inhibition of [3H]quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor M2 in rat brain membrane,Confirmatory,3385727.0,
392,142806,10,5,,103164643,2230,Active,12643977.0,81645.0,0.59,IC50,Inhibition of [3H]quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor M2 of rat heart,Confirmatory,3385727.0,
393,142833,7,5,,103164643,2230,Active,113121.0,25229.0,0.077,IC50,Displacement of [3H]-OXO-M (oxotremorine-M) from the central muscarinic receptor sites of the rat brain membranes,Confirmatory,,
394,142833,7,5,,103164643,2230,Active,113127.0,24260.0,0.077,IC50,Displacement of [3H]-OXO-M (oxotremorine-M) from the central muscarinic receptor sites of the rat brain membranes,Confirmatory,,
395,142833,7,5,,103164643,2230,Active,113130.0,25111.0,0.077,IC50,Displacement of [3H]-OXO-M (oxotremorine-M) from the central muscarinic receptor sites of the rat brain membranes,Confirmatory,,
396,142833,7,5,,103164643,2230,Active,113132.0,53949.0,0.077,IC50,Displacement of [3H]-OXO-M (oxotremorine-M) from the central muscarinic receptor sites of the rat brain membranes,Confirmatory,,
397,142833,7,5,,103164643,2230,Active,12643977.0,81645.0,0.077,IC50,Displacement of [3H]-OXO-M (oxotremorine-M) from the central muscarinic receptor sites of the rat brain membranes,Confirmatory,,
398,142842,7,2,,103164643,2230,Active,,,0.12,IC50,Compound was tested for its ability to inhibit muscarinic receptor in rat cerebral cortex using [3H]oxotremorine-M (OXO-M); Range is 75-170,Confirmatory,,
399,142844,7,2,,103164643,2230,Active,,,25.0,IC50,Compound was tested for its ability to inhibit muscarinic receptor in rat cerebral cortex using [3H]quinuclidinyl benzilate (QNB); Range is 10000-110000,Confirmatory,,
400,142864,7,2,,103164643,2230,Active,,,9.15,IC50,Compound was evaluated for the displacement of the muscarinic QNB in rat heart homogenate containing the pharmacologic M2 receptor (M2-QNB heart),Confirmatory,,
401,142917,4,6,,103164643,2230,Unspecified,,,,,Ratio of [3H]N-methylscopolamine (NMS) to [3H]oxotremorine (OXO) at muscarinic acetylcholine receptor from rat cortical homogenate.,Other,2362286.0,
402,142958,9,5,,103164643,2230,Active,12643977.0,81645.0,0.04,Ki,Inhibition of binding of [3H]quinuclidinyl benzilate to Muscarinic acetylcholine receptor M2 in rat cerebral cortical membranes,Confirmatory,9622546.0,
403,145683,7,4,,103164643,2230,Active,,,0.22399999999999998,Ki,Binding affinity for Nicotinic acetylcholine receptor site in rat cortex was determined using [3H]MCC as radioligand,Confirmatory,,
404,146461,9,2,,103164643,2230,Active,,,0.27,Ki,Inhibition of binding of [3H]nicotine to Nicotinic acetylcholine receptor alpha4-beta2 in rat cerebral cortical membranes at 100 uM concentration,Confirmatory,9622546.0,
405,146463,9,2,,103164643,2230,Active,,,0.27,Ki,The compound was evaluated for percentage inhibition of binding of [3H]- nicotine to Nicotinic acetylcholine receptor alpha4-beta2 in Rat Cerebral Cortical Membranes,Confirmatory,9622546.0,
406,166483,3,3,,103164643,2230,Unspecified,,,,,In vitro inhibition of maximum twitch height in electrically stimulated rabbit vas deferens.,Other,1613751.0,
407,166770,2,4,,103164643,2230,Unspecified,,,,,Percent maximum inhibition of the twitch response in the electrically stimulated rabbit vas deferens was determined.,Other,,
408,167153,3,6,,103164643,2230,Unspecified,,,,,Efficacy at muscarinic acetylcholine receptor M1 measured by the ability to inhibit the electrically stimulated twitch of the rabbit vas deferens,Other,1433209.0,
409,167656,4,4,,103164643,2230,Active,,,0.545,IC50,Compound was evaluated for the inhibition of the twitch response in the electrically stimulated rabbit vas deferens,Confirmatory,,
410,167809,5,4,,103164643,2230,Active,,,0.545,IC50,Efficacy at muscarinic acetylcholine receptor M1 measured by the ability to inhibit the electrically stimulated twitch of the rabbit vas deferens,Confirmatory,1433209.0,
411,167827,5,2,,103164643,2230,Active,,,0.545,IC50,In vitro inhibition of twitch height in electrically stimulated rabbit vas deferens,Confirmatory,1613751.0,
412,176362,8,1,,103164643,2230,Active,,,1.6,ED50,Concentration required to relax phenylephrine-precontracted aortic rings by 50% in endothelium intact rat aorta,Confirmatory,9703467.0,
413,176906,6,3,,103164643,2230,Unspecified,,,,,Dose producing 50% fall in blood pressure in anesthetized rats,Other,9435896.0,
414,176907,6,3,,103164643,2230,Unspecified,,,,,Dose producing 50% fall in heart rate in anesthetized rats,Other,9435896.0,
415,181414,3,3,,103164643,2230,Unspecified,,,,,Dose producing 50% fall in rhythmic slow wave activity in anesthetized rats,Other,9435896.0,
416,189455,3,4,,103164643,2230,Unspecified,,,,,Ability to stimulate phosphoinositol metabolism was examined in the rat cerebral cortex at 100 uM,Other,8464038.0,
417,189461,3,3,,103164643,2230,Unspecified,,,,,Stimulation of phosphoinositide (PI) metabolism in rat cortex at 100 uM,Other,8064804.0,
418,193260,2,5,,103164643,2230,Unspecified,,,,,Evaluated for the percentage efficacy in depolarizations of rat superior cervical ganglion,Other,,
419,193261,2,5,,103164643,2230,Unspecified,,,,,Evaluated for the percentage efficacy in rat hippocampal slice preparations,Other,,
420,193265,3,7,,103164643,2230,Unspecified,,,,,Central postsynaptic muscarinic activity was measured relative to muscurine (100%),Other,1732522.0,
421,193266,3,7,,103164643,2230,Unspecified,,,,,Neuronal postsynaptic muscarinic activity was measured relative to muscurine (100%),Other,1732522.0,
422,196226,3,4,,103164643,2230,Unspecified,,,,,Tested for agonist activity through assays of phosphoinositide (PI) metabolism in slices from rat cerebral cortex,Other,9111297.0,
423,197176,3,9,,103164643,2230,Unspecified,113121.0,25229.0,,,Central postsynaptic muscarinic activity was measured by slow depolarization of the rat cervical ganglion in M1 model,Other,1732522.0,
424,197188,2,5,,103164643,2230,Unspecified,,,,,Evaluated for the muscarinic potency in depolarizations of rat superior cervical ganglion,Other,,
425,197189,2,5,,103164643,2230,Unspecified,,,,,Evaluated for the muscarinic potency in rat hippocampal slice preparations,Other,,
426,197273,4,6,,103164643,2230,Unspecified,,,,,"Maximum stimulation of phosphatidyl inositol in rat hippocampal tissue, activity is expressed as percent of carbachol response",Other,7739014.0,
427,197332,3,9,,103164643,2230,Unspecified,113121.0,25229.0,,,Neuronal postsynaptic muscarinic activity was measured by firing rate of the rat hippocampal CA1 neurons in M1 model,Other,1732522.0,
428,202481,2,5,,103164643,2230,Unspecified,,,,,Phosphoinositide (PI) turnover was assessed by the ability to stimulate [3H]- inositol phosphate accumulation in human SK-N-SH neuroblastoma cells relative to carbachol,Other,,
429,225548,7,2,,103164643,2230,Active,,,0.024,IC50,Binding affinity against muscarinic receptor in rat brain membranes using oxotremorine-M as ligand,Confirmatory,9873644.0,
430,226748,3,4,,103164643,2230,Unspecified,,,,,Potency ratio of EC50 of the CHO cell lines to that of A9L cell lines was calculated.,Other,9873644.0,
431,227700,3,3,,103164643,2230,Unspecified,,,,,Anticonvulsant activity,Other,12873507.0,
432,227718,7,1,,103164643,2230,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
433,228726,3,4,,103164643,2230,Unspecified,,,,,Muscarinic agonist index (Ki in [3H]QNB / Ki in [3H]-OXO-M) was determined,Other,3385727.0,
434,228728,3,6,,103164643,2230,Unspecified,,,,,Ratio of the binding affinities against muscarinic M2 and muscarinic M1 receptors.,Other,7783150.0,
435,228962,3,6,,103164643,2230,Unspecified,,,,,Muscarinic agonist index calculated as [IC50(QNB)/IC50(Oxo-M)] X 0.162 values,Other,1995893.0,
436,229452,3,10,,103164643,2230,Unspecified,113121.0,25229.0,,,Efficacy ratio was determined against Muscarinic receptor using QNB/ OXO- M,Other,,
437,229452,3,10,,103164643,2230,Unspecified,113127.0,24260.0,,,Efficacy ratio was determined against Muscarinic receptor using QNB/ OXO- M,Other,,
438,229452,3,10,,103164643,2230,Unspecified,113130.0,25111.0,,,Efficacy ratio was determined against Muscarinic receptor using QNB/ OXO- M,Other,,
439,229452,3,10,,103164643,2230,Unspecified,113132.0,53949.0,,,Efficacy ratio was determined against Muscarinic receptor using QNB/ OXO- M,Other,,
440,229452,3,10,,103164643,2230,Unspecified,12643977.0,81645.0,,,Efficacy ratio was determined against Muscarinic receptor using QNB/ OXO- M,Other,,
441,229750,3,10,,103164643,2230,Unspecified,113121.0,25229.0,,,Ratio of inhibition of QNB to OXO-M binding to Muscarinic receptor,Other,1560440.0,
442,229750,3,10,,103164643,2230,Unspecified,113127.0,24260.0,,,Ratio of inhibition of QNB to OXO-M binding to Muscarinic receptor,Other,1560440.0,
443,229750,3,10,,103164643,2230,Unspecified,113130.0,25111.0,,,Ratio of inhibition of QNB to OXO-M binding to Muscarinic receptor,Other,1560440.0,
444,229750,3,10,,103164643,2230,Unspecified,113132.0,53949.0,,,Ratio of inhibition of QNB to OXO-M binding to Muscarinic receptor,Other,1560440.0,
445,229750,3,10,,103164643,2230,Unspecified,12643977.0,81645.0,,,Ratio of inhibition of QNB to OXO-M binding to Muscarinic receptor,Other,1560440.0,
446,230246,3,3,,103164643,2230,Unspecified,,,,,Ratio of NMS/oxo-M apparent binding affinities (Kapp),Other,3339620.0,
447,230681,3,7,,103164643,2230,Unspecified,,,,,Ratio of ability of compound for displacement of the muscarinic QNB in rat heart M2 receptor to that of displacement of the muscarinic QNB in a genetically transformed rat cell line (m1c2) transfected with cloned m1 receptors,Other,,
448,230682,3,4,,103164643,2230,Unspecified,,,,,Ratio of ability of compound to displace muscarinic antagonist [3H]cis-methyldioxolane to that of muscarinic agonist [3H]quinuclidinyl benzilate in rat cortical tissue,Other,,
449,230727,3,7,,103164643,2230,Unspecified,,,,,Ratio of the Ki (NMS) value to that of Ki (Oxo-M).,Other,7739014.0,
450,230833,3,4,,103164643,2230,Unspecified,,,,,M-1 selectivity expressed as M-2/M-1 index (Ki in [3H]-QNB / Ki in [3H]PZ) was determined,Other,3385727.0,
451,230876,3,5,,103164643,2230,Unspecified,,,,,Ratio of affinity versus antagonist [3H]-QNB divided by affinity versus agonist [3H]OXO-M,Other,10891110.0,
452,230877,3,10,,103164643,2230,Unspecified,113121.0,25229.0,,,Relative displacement of antagonist [3H]QNB and agonist [3H]-OXO-M from rat heart membranes,Other,10891110.0,
453,230877,3,10,,103164643,2230,Unspecified,113127.0,24260.0,,,Relative displacement of antagonist [3H]QNB and agonist [3H]-OXO-M from rat heart membranes,Other,10891110.0,
454,230877,3,10,,103164643,2230,Unspecified,113130.0,25111.0,,,Relative displacement of antagonist [3H]QNB and agonist [3H]-OXO-M from rat heart membranes,Other,10891110.0,
455,230877,3,10,,103164643,2230,Unspecified,113132.0,53949.0,,,Relative displacement of antagonist [3H]QNB and agonist [3H]-OXO-M from rat heart membranes,Other,10891110.0,
456,230877,3,10,,103164643,2230,Unspecified,12643977.0,81645.0,,,Relative displacement of antagonist [3H]QNB and agonist [3H]-OXO-M from rat heart membranes,Other,10891110.0,
457,230976,3,6,,103164643,2230,Unspecified,,,,,Ratio of the effectivie concentrations against muscarinic M2 and muscarinic M1 receptors.,Other,7783150.0,
458,231956,3,9,,103164643,2230,Unspecified,113118.0,1128.0,,,Ratio of displacement of NMS and Oxo-M from muscarinic receptor M1,Other,11597415.0,
459,232159,3,4,,103164643,2230,Unspecified,,,,,Ratio of 50% fall in blood pressure to that of rhythmic slow wave activity in anesthetized rats,Other,9435896.0,
460,232161,3,4,,103164643,2230,Unspecified,,,,,Ratio of 50% fall in heart rate to that of in blood pressure in anesthetized rats,Other,9435896.0,
461,232369,3,7,,103164643,2230,Unspecified,,,,,Ratio of Compound (IC50(nM) of QNB/ IC50(nM) of OXO-M),Other,1619616.0,
462,232606,3,7,,103164643,2230,Unspecified,,,,,Ratio of IC50 QNB to that of OXO-M was determined,Other,9435896.0,
463,232983,3,3,,103164643,2230,Unspecified,,,,,Relative efficacy determined by agonist index.,Other,7783150.0,
464,233564,3,7,,103164643,2230,Unspecified,,,,,The ratio of Kapp([3H]-NMS) / Kapp([3H]-OXO-M) was determined,Other,2319559.0,
465,234087,3,7,,103164643,2230,Unspecified,,,,,Selectivity for nicotinic agonist activity was determined between Ki for [3H]-OXO-M and to that for [3H]MCC,Other,,
466,322940,4,1,,103164643,2230,Active,113118.0,1128.0,29.5121,Ki,Binding affinity to human cloned muscarinic M1 receptor expressed in CHO cells,Confirmatory,18182302.0,
467,322941,5,1,,103164643,2230,Active,113122.0,1129.0,2.45471,Ki,Binding affinity to human cloned muscarinic M2 receptor expressed in CHO cells,Confirmatory,18182302.0,
468,322942,5,1,,103164643,2230,Unspecified,543761.0,1133.0,56.2341,Ki,Binding affinity to human cloned muscarinic M5 receptor expressed in CHO cells,Confirmatory,18182302.0,
469,382098,8,7,,103164643,2230,Unspecified,113121.0,25229.0,,IC50,Displacement of [3H]Quinuclidinyl benzilate from muscarinic M1 receptor in Wistar rat cortex synaptosomal membrane,Confirmatory,18359231.0,
470,416537,3,3,,103164643,2230,Unspecified,,,,,"Inhibition of scopolamine-induced immediate working memory deficit in NMRI mouse at 1 mg/kg, ip by Y-maze test relative to control",Other,19261477.0,
471,434959,1,1,,85788884,2230,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
472,437586,7,7,,103164643,2230,Unspecified,113121.0,25229.0,,IC50,Displacement of [3H]QNB from muscarinic M1 receptor in Wistar rat brain cortex membrane after 2 hrs by liquid scintillation counting,Confirmatory,19717214.0,
473,463106,1,2,,90341790,2230,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
474,477395,7,7,,103164643,2230,Unspecified,113121.0,25229.0,,IC50,Displacement of [3H]QNB from muscarinic M1 receptor in Wistar rat brain cortex after 2 hrs by liquid scintillation counting,Confirmatory,19595599.0,
475,477459,3,3,,103164643,2230,Unspecified,,,,,"Antiamnesic activity against scopolamine-induced dementia in Wistar rat assessed as basal latency period to reach shock free zone at 0.5 mg/kg, po",Other,19595599.0,
476,477460,3,3,,103164643,2230,Unspecified,,,,,"Antiamnesic activity against scopolamine-induced dementia in Wistar rat assessed as latency period to improve memory at 0.5 mg/kg, po",Other,19595599.0,
477,477461,3,3,,103164643,2230,Unspecified,,,,,"Antiamnesic activity against scopolamine-induced memory loss and learning impairment in Wistar rat assessed as transfer latency period to reach from open arm to closed arm ends measured on day 1 at 0.5 mg/kg, po by elevated plus maze test",Other,19595599.0,
478,477462,3,3,,103164643,2230,Unspecified,,,,,"Antiamnesic activity against scopolamine-induced memory loss and learning impairment in Wistar rat assessed as transfer latency period to reach from open arm to closed arm ends measured on day 2 at 0.5 mg/kg, po by elevated plus maze test",Other,19595599.0,
479,477463,3,3,,103164643,2230,Active,,,,,"Antiamnesic activity against scopolamine-induced memory loss and learning impairment in Wistar rat at 0.5 mg/kg, po by Y maze test",Other,19595599.0,
480,477466,3,3,,103164643,2230,Unspecified,,,,,Toxicity in po dosed Wistar rat assessed as mortality within 1 week,Other,19595599.0,
481,485281,1,1,,11110759,2230,Inactive,254220970.0,,0.3162,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
482,485290,1,1,,11110759,2230,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
483,485290,1,1,,26755647,2230,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
484,485295,1,2,,90341790,2230,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
485,485297,1,1,,90341790,2230,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
486,485298,1,1,,90341790,2230,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
487,485313,1,2,,90341790,2230,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
488,485342,1,2,,90341790,2230,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
489,485345,1,2,,90341790,2230,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
490,485366,1,2,,90341790,2230,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
491,485368,1,2,,90341790,2230,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
492,488772,1,1,,90341790,2230,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
493,488773,1,2,,90341790,2230,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
494,488816,1,1,,90341790,2230,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
495,488837,1,1,,90341790,2230,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
496,488949,1,2,,90341790,2230,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
497,488953,1,1,,90341790,2230,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
498,488978,1,1,,90341790,2230,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
499,488981,1,1,,90341790,2230,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
500,488982,1,1,,90341790,2230,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
501,488983,1,1,,90341790,2230,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
502,493106,1,1,,90341790,2230,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
503,493107,1,1,,90341790,2230,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
504,493153,1,1,,90341790,2230,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
505,493153,1,1,,90341790,2230,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
506,493164,1,2,,90341790,2230,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
507,493164,1,2,,90341790,2230,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
508,493164,1,2,,90341790,2230,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
509,504327,1,1,,11110759,2230,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
510,504327,1,1,,90341790,2230,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
511,504332,1,1,,11110759,2230,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
512,504332,1,1,,90341790,2230,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
513,504536,1,1,,90341790,2230,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
514,504547,1,1,,90341790,2230,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
515,504548,1,2,,90341790,2230,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
516,504749,1,3,,26755647,2230,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
517,504749,1,3,,104171107,2230,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
518,504749,1,3,1.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
519,504749,1,3,2.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
520,504749,1,3,3.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
521,504749,1,3,4.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
522,504749,1,3,5.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
523,504749,1,3,6.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
524,504749,1,3,7.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
525,504749,1,3,8.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
526,504749,1,3,9.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
527,504749,1,3,10.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
528,504749,1,3,11.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
529,504749,1,3,12.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
530,504749,1,3,13.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
531,504749,1,3,14.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
532,504749,1,3,15.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
533,504749,1,3,16.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
534,504749,1,3,17.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
535,504749,1,3,18.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
536,504749,1,3,19.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
537,504749,1,3,20.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
538,504749,1,3,21.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
539,504749,1,3,22.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
540,504749,1,3,23.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
541,504749,1,3,24.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
542,504749,1,3,25.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
543,504749,1,3,26.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
544,504749,1,3,27.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
545,504749,1,3,28.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
546,504749,1,3,29.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
547,504749,1,3,30.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
548,504749,1,3,31.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
549,504749,1,3,32.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
550,504749,1,3,33.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
551,504749,1,3,34.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
552,504749,1,3,35.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
553,504749,1,3,36.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
554,504749,1,3,37.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
555,504749,1,3,38.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
556,504749,1,3,39.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
557,504749,1,3,40.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
558,504749,1,3,41.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
559,504749,1,3,42.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
560,504749,1,3,43.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
561,504749,1,3,44.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
562,504749,1,3,45.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
563,504749,1,3,46.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
564,504749,1,3,47.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
565,504749,1,3,48.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
566,504749,1,3,49.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
567,504749,1,3,50.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
568,504749,1,3,51.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
569,504749,1,3,52.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
570,504749,1,3,53.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
571,504749,1,3,54.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
572,504749,1,3,55.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
573,504749,1,3,56.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
574,504749,1,3,57.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
575,504749,1,3,58.0,26755647,2230,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
576,504749,1,3,59.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
577,504749,1,3,60.0,104171107,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
578,504749,1,3,61.0,26755647,2230,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
579,504810,1,2,,90341790,2230,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
580,504812,1,2,,90341790,2230,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
581,504832,1,1,,104171107,2230,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
582,504834,1,1,,104171107,2230,Inconclusive,,,16.9441,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
583,504836,1,2,,90341790,2230,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
584,504845,1,1,,90341790,2230,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
585,504845,1,1,,104171107,2230,Inconclusive,86301163.0,5999.0,3.3587,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
586,504847,1,1,,11110759,2230,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
587,504847,1,1,,90341790,2230,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
588,504847,1,1,,104171107,2230,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
589,504865,1,1,,11110759,2230,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
590,504865,1,1,,90341790,2230,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
591,504865,1,1,,104171107,2230,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
592,540256,1,2,,90341790,2230,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
593,540276,1,2,,11110758,2230,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
594,540276,1,2,,11110759,2230,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
595,540276,1,2,,26755647,2230,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
596,540276,1,2,,50110935,2230,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
597,540276,1,2,,50110936,2230,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
598,540276,1,2,,90341790,2230,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
599,588349,1,1,,90341790,2230,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
600,588378,1,1,,90341790,2230,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
601,588453,1,1,,90341790,2230,Inactive,8659577.0,58819.0,1.0,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
602,588456,1,1,,90341790,2230,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
603,588579,1,1,,11110759,2230,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
604,588579,1,1,,90341790,2230,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
605,588579,1,1,,104171107,2230,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
606,588795,1,1,,90341790,2230,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
607,588834,2,1,,26755647,2230,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
608,602332,1,1,,11110759,2230,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
609,602332,1,1,,90341790,2230,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
610,602332,1,1,,104171107,2230,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
611,624030,1,2,,104171107,2230,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
612,624031,1,2,,104171107,2230,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
613,624032,1,2,,104171107,2230,Inactive,8393992.0,24660.0,40.5334,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
614,624044,1,2,,104171107,2230,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
615,624101,1,2,,85789413,2230,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
616,624146,1,1,,90341790,2230,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
617,624147,1,1,,90341790,2230,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
618,624148,1,2,,90341790,2230,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
619,624149,1,1,,90341790,2230,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
620,624151,1,1,,85789413,2230,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
621,624156,1,1,,85788884,2230,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
622,624170,1,1,,104171107,2230,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
623,624172,1,1,,104171107,2230,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
624,624173,1,3,,104171107,2230,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
625,624296,1,1,,104171107,2230,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
626,624297,1,1,,104171107,2230,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
627,624455,1,1,,90341790,2230,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
628,651631,4,1,,144203630,2230,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
629,651632,4,1,,144203630,2230,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
630,651633,4,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
631,651634,4,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
632,651635,1,3,,11110759,2230,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
633,651635,1,3,,90341790,2230,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
634,652048,1,2,,144203630,2230,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
635,652051,1,1,,144203630,2230,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
636,652106,1,1,,90341790,2230,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
637,686977,2,1,,49698472,2230,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
638,686978,1,1,,144203630,2230,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
639,686979,1,1,,144203630,2230,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
640,720516,2,1,,144203630,2230,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
641,720532,1,1,,11110759,2230,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
642,720532,1,1,,144203630,2230,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
643,720533,1,1,,11110759,2230,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
644,720533,1,1,,144203630,2230,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
645,720538,1,2,,90341790,2230,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
646,720552,2,1,,144203630,2230,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
647,720559,1,2,,90341790,2230,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
648,720572,1,2,,90341790,2230,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
649,720573,1,2,,90341790,2230,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
650,720634,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
651,720635,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
652,720637,2,1,,144203630,2230,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
653,720674,2,2,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
654,720675,2,2,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
655,720678,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
656,720679,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
657,720680,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
658,720681,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
659,720682,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
660,720683,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
661,720684,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
662,720685,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
663,720686,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
664,720687,2,2,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
665,720691,4,1,,144203630,2230,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
666,720692,3,1,,144203630,2230,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
667,720693,3,1,,144203630,2230,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
668,720719,2,1,,144203630,2230,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
669,720725,2,1,,144203630,2230,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
670,743012,3,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
671,743014,3,1,,144203630,2230,Inconclusive,,,14.9601,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
672,743015,3,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
673,743033,3,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
674,743035,2,1,,144203630,2230,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
675,743036,2,1,,144203630,2230,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
676,743040,3,1,,144203630,2230,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
677,743041,3,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
678,743042,3,1,,144203630,2230,Inactive,124375976.0,367.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
679,743053,2,1,,144203630,2230,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
680,743054,2,1,,144203630,2230,Inconclusive,124375976.0,367.0,21.1317,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
681,743063,2,1,,144203630,2230,Inconclusive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
682,743064,3,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
683,743065,3,1,,144203630,2230,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
684,743066,3,1,,144203630,2230,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
685,743067,2,1,,144203630,2230,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
686,743069,2,1,,144203630,2230,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
687,743074,2,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
688,743075,2,1,,144203630,2230,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
689,743077,2,1,,144203630,2230,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
690,743078,2,1,,144203630,2230,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
691,743079,3,1,,144203630,2230,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
692,743080,3,1,,144203630,2230,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
693,743081,3,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
694,743083,3,1,,144203630,2230,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
695,743084,3,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
696,743085,3,1,,144203630,2230,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
697,743086,3,1,,144203630,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
698,743091,2,1,,144203630,2230,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
699,743094,3,1,,144203630,2230,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
700,743122,2,1,,144203630,2230,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
701,743139,2,1,,144203630,2230,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
702,743140,2,1,,144203630,2230,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
703,743191,3,1,,170466659,2230,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
704,743194,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
705,743199,2,1,,170466659,2230,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
706,743202,4,1,,170466659,2230,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
707,743203,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
708,743205,1,1,,90341790,2230,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
709,743205,1,1,,90341790,2230,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
710,743206,1,1,,90341790,2230,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
711,743206,1,1,,90341790,2230,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
712,743207,1,1,,90341790,2230,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
713,743207,1,1,,90341790,2230,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
714,743209,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
715,743210,4,1,,170466659,2230,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
716,743211,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
717,743212,3,1,,170466659,2230,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
718,743213,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
719,743215,3,1,,170466659,2230,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
720,743217,3,1,,170466659,2230,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
721,743218,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
722,743219,3,1,,170466659,2230,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
723,743220,3,1,,170466659,2230,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
724,743221,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
725,743222,3,1,,170466659,2230,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
726,743223,3,1,,170466659,2230,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
727,743224,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
728,743225,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
729,743226,2,1,,170466659,2230,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
730,743227,2,1,,170466659,2230,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
731,743228,3,1,,170466659,2230,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
732,743239,2,1,,170466659,2230,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
733,743240,2,1,,170466659,2230,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
734,743241,2,1,,170466659,2230,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
735,743242,2,1,,170466659,2230,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
736,743244,1,1,,90341790,2230,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
737,743244,1,1,,144203630,2230,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
738,743344,1,1,,124879235,2230,Inactive,,,14.9502,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
739,743345,1,1,,124879235,2230,Inactive,,,0.0211,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
740,743346,1,1,,124879235,2230,Inactive,,,13.3244,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
741,743347,1,1,,124879235,2230,Inactive,,,0.0943,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
742,781325,1,2,,103164643,2230,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 2009,Other,24249037.0,
743,1108432,1,2,,103164643,2230,Unspecified,,,240.0,Ki,Displacement of [3H]alpha-bungarotoxin from nAChR in honeybee head membrane after 60 min by scintillation counting,Confirmatory,,
744,1108433,2,1,,103164643,2230,Unspecified,,,516.0,Ki,Displacement of [3H]alpha-bungarotoxin from nAChR in Musca domestica (house fly) head membrane after 60 min by scintillation counting,Confirmatory,,
745,1117298,1,2,,170466659,2230,Inactive,,,44.6684,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
746,1117304,1,2,,170466659,2230,Inactive,,,44.6684,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
747,1117305,1,2,,170466659,2230,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
748,1117310,1,1,,170466659,2230,Inactive,,,44.6684,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
749,1117312,1,1,,170466659,2230,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
750,1117314,1,1,,170466659,2230,Inactive,,,44.6684,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
751,1117326,1,1,,170466659,2230,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
752,1117329,1,1,,170466659,2230,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
753,1117336,1,1,,170466659,2230,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
754,1117340,1,1,,170466659,2230,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
755,1117341,1,1,,170466659,2230,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
756,1117342,1,1,,170466659,2230,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
757,1117343,1,1,,170466659,2230,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
758,1117346,1,1,,170466659,2230,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
759,1159509,1,1,,170466659,2230,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
760,1159515,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
761,1159516,1,1,,170466659,2230,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
762,1159517,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
763,1159518,1,1,,170466659,2230,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
764,1159519,1,1,,170466659,2230,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
765,1159520,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
766,1159521,1,1,,170466659,2230,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
767,1159523,1,1,,170466659,2230,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
768,1159525,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
769,1159526,1,1,,170466659,2230,Inconclusive,119627033.0,3725.0,6.74,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
770,1159527,1,1,,170466659,2230,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
771,1159528,1,1,,170466659,2230,Inconclusive,119627033.0,3725.0,13.4481,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
772,1159529,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
773,1159531,1,1,,170466659,2230,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
774,1159551,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
775,1159552,1,1,,170466659,2230,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
776,1159553,2,1,,170466659,2230,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
777,1159555,1,1,,170466659,2230,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
778,1159580,2,1,,268734511,2230,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
779,1159580,2,1,,273002691,2230,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
780,1159607,2,1,,312596620,2230,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
781,1159614,1,2,,170466659,2230,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
782,1224824,1,1,,124879235,2230,Inactive,,,0.1049,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
783,1224825,1,1,,124879235,2230,Inactive,,,0.0053,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
784,1224834,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
785,1224835,1,1,,170466659,2230,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
786,1224836,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
787,1224837,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
788,1224838,1,1,,170466659,2230,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
789,1224839,1,1,,170466659,2230,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
790,1224840,3,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
791,1224841,3,1,,170466659,2230,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
792,1224842,3,1,,170466659,2230,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
793,1224843,1,1,,170466659,2230,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
794,1224844,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
795,1224845,1,1,,170466659,2230,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
796,1224846,1,1,,170466659,2230,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
797,1224847,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
798,1224848,3,1,,170466659,2230,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
799,1224849,3,1,,170466659,2230,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
800,1224857,2,1,,124879235,2230,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
801,1224857,2,1,,170466659,2230,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
802,1224859,2,1,,90341790,2230,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
803,1224859,2,1,,124879235,2230,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
804,1224859,2,1,,170466659,2230,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
805,1224863,1,1,,316919985,2230,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
806,1224867,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
807,1224868,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
808,1224869,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
809,1224870,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
810,1224871,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
811,1224872,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
812,1224873,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
813,1224874,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
814,1224875,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
815,1224876,1,1,,170466659,2230,Inconclusive,,,4.7716,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
816,1224877,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
817,1224878,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
818,1224879,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
819,1224880,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
820,1224881,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
821,1224882,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
822,1224883,1,1,,170466659,2230,Inconclusive,,,4.7716,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
823,1224884,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
824,1224885,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
825,1224886,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
826,1224887,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
827,1224888,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
828,1224889,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
829,1224890,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
830,1224892,1,1,,170466659,2230,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
831,1224893,1,1,,170466659,2230,Inconclusive,66775687.0,9970.0,31.618000000000002,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
832,1224894,1,1,,170466659,2230,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
833,1224895,1,1,,170466659,2230,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
834,1224896,1,1,,170466659,2230,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
835,1257357,1,1,,103164643,2230,Unspecified,5921694.0,100135490.0,33.73,IC50,Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in guinea pig ventricular myocytes,Confirmatory,,
836,1259241,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
837,1259242,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
838,1259243,1,1,,170466659,2230,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
839,1259244,1,1,,170466659,2230,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
840,1259247,1,1,,170466659,2230,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
841,1259248,1,1,,170466659,2230,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
842,1259252,1,1,,124879235,2230,Inconclusive,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
843,1259253,1,1,,124879235,2230,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
844,1259255,1,1,,124879235,2230,Inconclusive,169655958.0,,10.4904,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
845,1259256,1,1,,124879235,2230,Inconclusive,169655958.0,,18.6548,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
846,1259310,1,1,,332949689,2230,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
847,1259344,1,1,,144203630,2230,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
848,1259355,1,1,,26755647,2230,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
849,1259356,1,1,,144203630,2230,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
850,1259364,1,1,,170466659,2230,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
851,1259365,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
852,1259366,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
853,1259367,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
854,1259368,1,1,,170466659,2230,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
855,1259369,1,1,,170466659,2230,Inconclusive,109731339.0,2737.0,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
856,1259377,1,1,,170466659,2230,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
857,1259378,1,1,,170466659,2230,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
858,1259379,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
859,1259380,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
860,1259381,1,1,,170466659,2230,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
861,1259382,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
862,1259383,1,1,,170466659,2230,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
863,1259384,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
864,1259385,1,1,,170466659,2230,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
865,1259386,1,1,,170466659,2230,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
866,1259387,1,1,,170466659,2230,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
867,1259388,1,1,,170466659,2230,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
868,1259390,1,1,,170466659,2230,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
869,1259391,1,1,,170466659,2230,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
870,1259392,1,1,,170466659,2230,Active,109731339.0,2737.0,13.8548,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
871,1259393,1,1,,170466659,2230,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
872,1259394,1,1,,170466659,2230,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
873,1259395,1,1,,170466659,2230,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
874,1259396,1,1,,170466659,2230,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
875,1259400,1,1,,170466659,2230,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
876,1259401,1,1,,170466659,2230,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
877,1259402,1,1,,170466659,2230,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
878,1259403,1,1,,170466659,2230,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
879,1259404,1,1,,170466659,2230,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
880,1259407,1,1,,363905638,2230,Active,,,,,CCRIS mutagenicity studies,Other,,
881,1259408,1,1,,363897896,2230,Active,,,,,GENE-TOX mutagenicity studies,Other,,
882,1259416,1,2,,375177857,2230,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
883,1259421,1,1,,340083646,2230,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
884,1259421,1,1,,375177857,2230,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
885,1259423,1,2,,354786137,2230,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
886,1259423,1,2,,354815344,2230,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
887,1259423,1,2,,354921695,2230,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
888,1259423,1,2,,354936057,2230,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
889,1259423,1,2,,354981974,2230,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
